Business Context and Reporting Period
Company: enGene Holdings Inc. (trading as Engene Therapeutics Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2026
Event: Entry into a Material Definitive Agreement (Second Amendment to Loan and Security Agreement) and issuance of unregistered equity securities (warrants).
Key Financial Metrics and Debt Structure
This filing details a restructuring of the company's debt facility rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Total Facility Capacity: Increased from $50 million to $125 million.
- Initial Draw (Tranche 1): $25 million advanced on January 20, 2026, used to refinance prior outstanding term loans.
- Future Tranches (Milestone-Dependent):
- Up to $35 million (Clinical Milestone).
- Up to $20 million (Approval Milestone).
- Up to $20 million (Commercial Milestone).
- Up to $25 million (Uncommitted tranche subject to lender approval).
- Maturity Date: January 1, 2030.
- Interest Rate: Monthly cash interest at the greater of (Prime Rate + 2.25%, capped at 10.25%) or 9.25%.
- Fees:
- End of term fee: 5.95% of aggregate principal advanced.
- Facility charge: 0.50% to 0.75% of principal advanced per tranche.
- Collateral: Senior security interest in all personal property and assets, including Intellectual Property.
Material Changes Versus Prior Period
The Second Amendment significantly altered the terms of the Prior Loan Agreement (dated December 22, 2023, and amended December 18, 2024):
- Capacity Expansion: The total available term loan facility was increased by $75 million (from $50 million to $125 million).
- Extension: The maturity date was extended to January 1, 2030.
- Equity Component: Introduction of a warrant issuance requirement tied to loan advances, which was not present in the same form in the prior agreement.
Guidance, Outlook, and Unusual Items
Warrant Issuance (Unregistered Securities):
- Terms: Warrants issued to lenders equal to 1.50% of the aggregate principal amount of each advance, divided by an exercise price of $9.18 per share.
- Initial Issuance: 40,850 warrants issued on the Closing Date corresponding to the $25 million Tranche 1 Advance.
- Maximum Potential Issuance: Up to 204,248 warrants if the full $125 million facility is drawn.
- Exercise Period: Seven years from issuance.
- Regulatory Status: Issued pursuant to Section 4(a)(2) of the Securities Act of 1933 (exempt from registration).
Investor Verification Checklist
- Verify the current status of the "Clinical," "Approval," and "Commercial" milestones defined in the Amended Loan Agreement to assess the likelihood of future funding tranches.
- Confirm the current Prime Rate to calculate the exact effective interest rate (Prime + 2.25% vs. 9.25% floor).
- Review the dilution impact of the maximum 204,248 potential warrant exercises on existing shareholders.
- Examine the specific definitions of the milestones in Exhibit 10.1 to understand the conditions precedent for the remaining $100 million in potential funding.
- Assess the company's liquidity position post-refinancing, noting that the initial $25 million was used to pay off prior debt rather than providing new net cash.